FDA hungrily eyes industry's deep pockets; More calls for genetic oversight

WASHINGTON - Significant agreements reached by representatives from the biotech and pharmacuetical industries and the FDA in negotiations over a new Prescription Drug User Fee Act (PDUFA) could be jeopardized by deadlocks on some of the most contentious issues, especially the amount of money industry will pay for reviews of drug and biological applications and the scope of the commitments FDA is willing to make in order to receive the industry's financial aid.

Negotiators for the Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers Assocation (PhRMA) disagree with FDA not only about the amount of money the agency wants to collect, but also about the philosophy underlying the request. FDA, like virtually all government agencies, is under pressure from both the White House and Congress to reduce its budget. The Office of Management and Budget has asked FDA to trim its current budget by 3 percent in its next request.

FDA negotiators want industry either to persuade Congress to maintain the current level of appropriations or make up the shortfall of about

Read the full 1711 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE